Archive for October, 2015

(VBIV) & (SVACF) To Hold Joint Conference Call Over Proposed Merger

CAMBRIDGE, Mass. and VANCOUVER, British Columbia, Oct. 30, 2015  — VBI Vaccines Inc. (NASDAQ:VBIV) (“VBI”) and SciVac Therapeutics Inc. (TSX:VAC) (OTCQX:SVACF) (“SciVac”) will host a joint conference call for their respective shareholders at 3:00 P.M. Eastern Time on Thursday, November 5, 2015. The call will be hosted by Jeff Baxter, President & CEO of VBI, and Dr. Curtis Lockshin, CEO of SciVac, who will together discuss the previously announced entry into a merger agreement whereby, subject to the satisfaction of certain conditions, a wholly owned subsidiary of SciVac will merge with and into VBI, with VBI surviving as a wholly owned subsidiary of SciVac. The conference call will provide shareholders of VBI and SciVac with an opportunity to ask questions regarding the proposed merger.

The conference call registration information is listed below:

CONFERENCE CALL INFORMATION:

WHEN: Thursday, November 5, 2015, 3:00 P.M. Eastern Time

TO REGISTER: Please visit: http://dpregister.com/10075803 to receive dial-in instructions for the conference call

For those shareholders unable to participate in the conference call, a transcript will be available on VBI’s website at www.vbivaccines.com and will be filed with the U.S Securities and Exchange Commission and available at www.sec.gov.

About SciVac Therapeutics Inc.

SciVac Therapeutics Inc., headquartered in Rehovot Israel, is in the business of developing, producing and marketing biological products for human healthcare. SciVac’s flagship product, Sci-B-Vac™, is a recombinant third-generation hepatitis B vaccine. SciVac also offers contract development and manufacturing services to the life sciences and biotechnology markets.

Website Home: http://www.scivactherapeutics.com

Investors: http://ir.scivactherapeutics.com/

About VBI Vaccines Inc.

VBI Vaccines Inc. (“VBI”) is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. VBI’s eVLP vaccine platform allows for the design of enveloped (“e”) virus-like particle (“VLP”) vaccines that closely mimic the target virus. VBI’s lead eVLP asset is a prophylactic Cytomegalovirus (“CMV”) vaccine; VBI has initiated work for GMP manufacturing of its CMV candidate for use in formal preclinical and Phase I trials. VBI’s second platform is a thermostable technology that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. VBI has completed proof of concept thermostability studies on a number of vaccine and biologic targets. VBI is headquartered in Cambridge, MA with research facilities in Ottawa, Canada.

Website Home: http://www.vbivaccines.com/

News and Insights: http://www.vbivaccines.com/wire/

Investors: http://ir.vbivaccines.com/

Important Information For Investors And Stockholders

This communication does not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities or a solicitation of any vote or approval. This communication relates to a proposed business combination between VBI Vaccines Inc. (“VBI”) and SciVac Therapeutics Inc. (“SciVac”). In connection with this proposed business combination, VBI and/or SciVac will file relevant materials with the Securities Exchange Commission (the “SEC”) and applicable Canadian securities regulatory authorities (“Canadian Securities Commissions”), including a SciVac registration statement on Form F-4 or S-4 that will include a proxy statement of VBI and constitute a prospectus of SciVac. INVESTORS AND SECURITY HOLDERS OF VBI AND SCIVAC ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS THAT MAY BE FILED WITH THE SEC AND THE CANADIAN SECURITIES COMMISSIONS CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Any definitive proxy statement (if and when available) will be mailed to stockholders of VBI. Investors and security holders will be able to obtain free copies of these documents (if and when available) and other documents filed with the SEC by VBI and/or SciVac through the website maintained by the SEC at www.sec.gov and, in the case of documents of SciVac filed with the Canadian Securities Commissions, on SciVac’s SEDAR profile on www.sedar.com. Copies of the documents filed with the SEC by VBI will be available free of charge on VBI’s website at http://www.vbivaccines.com or by contacting VBI’s Investor Relations Department by email at ir@vbivaccines.com or by phone at (617) 830-3031 x128. Copies of the documents filed with the SEC and the Canadian Securities Commissions by SciVac will be available free of charge on SciVac’s website at www.scivactherapeutics.com or by contacting SciVac’s Investor Relations Department by email at jmartin@scivactherapeutics.com or by phone at (305) 575-4207.

Participants in Solicitation

VBI, SciVac, their respective directors and certain of their respective executive officers may be considered participants in the solicitation of proxies in connection with the proposed transaction. Information about the directors and executive officers of VBI is set forth in the proxy statement for VBI’s 2015 Annual Meeting of Stockholders, which was filed with the SEC on April 15, 2015 and available for review at www.sec.gov. Information about the directors and executive officers of SciVac is set forth in its Management Information Circular, furnished as Exhibit 99.1 to SciVac’s Form 6-K, furnished to the SEC on September 2, 2015 and available for review at www.sec.gov.

These documents can be obtained free of charge from the sources indicated above. Additional information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC and with the Canadian Securities Commissions when they become available.

Cautionary Statement on Forward-looking Information

Certain statements in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation (collectively, “forward-looking statements”) that may not be based on historical fact, but instead relate to future events, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. All statements other than statements of historical fact included in this release are forward-looking statements, including statements regarding: the ability of SciVac and VBI to consummate the transactions contemplated by the merger agreement, whereby, subject to the satisfaction of certain conditions, a wholly owned subsidiary of SciVac will merge with and into VBI, with VBI surviving as a wholly owned subsidiary of SciVac (the “Agreement); the anticipated benefits of the merger contemplated by the Agreement; and statements regarding the operation of each of VBI and SciVac’s businesses, including the expected development and/or commercialization of each of VBI and SciVac’s products.

Such forward-looking statements are based on a number of assumptions, including assumptions regarding the ability of the parties to satisfy, in a timely manner, the conditions contained in the Agreement; the successful development and/or commercialization of VBI and SciVac’s respective products, including the receipt of necessary regulatory approvals; general economic conditions; that the parties’ respective businesses are able to operate as anticipated without interruptions; competitive conditions; and changes in laws, rules and regulations applicable to VBI and SciVac.

Although management of VBI and SciVac believe that the assumptions made and expectations represented by such statements are reasonable, there can be no assurance that a forward-looking statement contained herein will prove to be accurate. Actual results and developments may differ materially from those expressed or implied by the forward-looking statements contained herein and even if such actual results and developments are realized or substantially realized, there can be no assurance that they will have the expected consequences or effects. Factors which could cause actual results to differ materially from current expectations include: non-completion of the transactions contemplated by the Agreement, including due to the parties failing to receive the necessary shareholder, stock exchange and regulatory approvals or the inability of the parties to satisfy in a timely manner and on satisfactory terms the necessary conditions; the failure to successfully develop or commercialize the parties’ respective products; adverse changes in general economic conditions or applicable laws, rules and regulations; and other factors detailed from time to time in each of VBI and SciVac’s periodic disclosure.

Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on the parties’ current expectations and neither party undertakes an obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange), accepts responsibility for the adequacy or accuracy of this news release.

CONTACT: SciVac Contact

         Curtis Lockshin, Chief Executive Officer
         Phone: +972-8-948-0625
         Email: lockshin@scivactherapeutics.com

         SciVac Investor Contact

         James Martin, Chief Financial Officer
         Phone: (305) 575-4207
         Email: jmartin@scivactherapeutics.com

         VBI Contact

         Perri Maduri, Communications Executive
         Phone: (617) 830-3031 x124
         Email: ir@vbivaccines.com

         VBI Investor Contact

         Nell Beattie
         Director, Corporate Development and Investor Relations
         Tel. (617) 830-3031 x128
         Email: nbeattie@vbivaccines.com
Friday, October 30th, 2015 Uncategorized Comments Off on (VBIV) & (SVACF) To Hold Joint Conference Call Over Proposed Merger

(AVID) Everywhere for Audio Continues to Deliver Groundbreaking Innovations

Powered by the MediaCentral Platform, the Portable and Affordable Ergonomic Surface Provides Intelligent, Versatile Studio Control

NEW YORK CITY, Oct. 30, 2015  — AES (Booth #718) Avid® (Nasdaq:AVID) today introduced Pro Tools® | Dock, a portable, affordable surface that gives audio and music professionals intelligent studio control. Delivering on Avid Everywhere™, Pro Tools | Dock gives users the power and control to create better sounding mixes more efficiently. Working together with an iPad running the free Pro Tools | Control app, it gives users the access, integration, and precision they need to edit and mix projects faster.

Powered by the Avid MediaCentral™ Platform, Pro Tools | Dock is based on the advanced touchscreen workflows of the award-winning Pro Tools | S6 and the hybrid touchscreen/hardware control of the bestselling Avid Artist | Control surface. Users can navigate large projects quickly and access any track instantly on the iPad touchscreen.

With Pro Tools | Dock, users can work with their favorite EUCON-enabled DAWs and video editing tools, including Pro Tools, Media Composer®, Logic Pro X, Cubase, and Premiere Pro. When paired with Pro Tools | S3, users gain new timesaving touch workflows and custom control making it ideal for mixing music and post projects in smaller spaces—and on smaller budgets.

“With Avid Everywhere we strive to deliver innovative solutions to help our customers bring their creative ideas to life,” said Kyle Kim-Hays, senior vice president and chief marketing officer, Avid. “Pro Tools | Dock gives audio professionals the tactile precision they need to focus on their mix with their ears instead of their eyes, enabling them to create better sounding mixes faster.”

Availability
Pro Tools | Dock will be available in Q1 2016.

Notes to editors
Pro Tools | Dock enhances the free Pro Tools | Control iOS app and the Pro Tools | S3 control surface, allowing music and audio professionals and aspiring pros to:

  • Get extensive touchscreen control – Pro Tools | Dock will quickly connect with a user’s iPad and the free Pro Tools | Control iOS app, providing intelligent control of audio and video projects. The app offers a host of touch controls and visual feedback to improve efficiency, allowing users to navigate huge sessions with ease and bring the channels they’re looking for to the surface quickly.
  • Enhance existing workflows with EUCON – Pro Tools | Dock features EUCON™, a high-speed Ethernet-based technology that enables the hardware to communicate directly with EUCON-enabled applications. This lets users work on a Pro Tools project, then switch to Logic Pro X, Cubase, Media Composer, Premiere Pro, and any other EUCON-compatible audio and video software—in sequence or in parallel—in seconds.
  • Get deep Pro Tools integration – when paired with Pro Tools or Pro Tools | HD, Pro Tools | Dock becomes an extension of the software. Users can access hundreds of key commands, shortcuts, functions, and UI elements without clicking a mouse. Users can even create custom soft keys to perform practically any Pro Tools function and recall Layouts to the surface with a single button press.
  • Bring enhanced touch workflows to Pro Tools | S3 – pairing Pro Tools | Dock with a Pro Tools | S3 control surface delivers even more timesaving workflows. Users can also view additional visual feedback to enhance their mixing experience.
  • Adjust parameters with a twist – Pro Tools | Dock provides eight touch-sensitive Soft Knobs that extend the functionality of Pro Tools | Control. These push-top rotary controls enable users to interact with whatever knob set they’ve selected in the app. By making adjustments with physical controls, users don’t have to focus on the screen, enabling them to really listen to how their adjustments affect their mix.
  • Speed up tasks with Soft Keys – users can click through frequently performed editing and mixing tasks or adapt the Dock to their unique workflow by programming macros to perform more complex tasks.
  • Navigate the project their way – users can quickly access any channel with the color-coded Track Tiles and Universe view—no matter how big the session.
  • Get their hands on important channels – users can work with multiple tracks in Pro Tools | Control, but when they need to focus on a specific track—or want more tactile precision—they can use a single “attention” channel. Users simply select any track from the touchscreen and the channel maps directly to the Dock’s surface controls.
  • Automate tracks with ease – with 12 dedicated automation switches, users can toggle modes and write automation directly from the surface.

For a full list if features visit: http://connect.avid.com/ProToolsDocksignup.html

About Avid
Through Avid Everywhere™, Avid delivers the industry’s most open, innovative and comprehensive media platform connecting content creation with collaboration, asset protection, distribution and consumption. Media organizations and creative professionals use Avid solutions to create the most listened to, most watched and most loved media in the world—from the most prestigious and award-winning feature films, to the most popular television shows, news programs and televised sporting events, as well as a majority of today’s most celebrated music recordings and live concerts. Industry leading solutions include Pro Tools®, Media Composer®, ISIS®, Interplay®, ProSet and RealSet, Maestro, PlayMaker, and Sibelius®. For more information about Avid solutions and services, visit www.avid.com, connect with Avid on Facebook, Instagram, Twitter, YouTube, LinkedIn, or subscribe to Avid Blogs.

© 2015 Avid Technology, Inc. All rights reserved. Avid, the Avid logo, Avid Everywhere, EUCON, iNEWS, Interplay, ISIS, AirSpeed, Media Composer, Pro Tools, and Sibelius are trademarks or registered trademarks of Avid Technology, Inc. or its subsidiaries in the United States and/or other countries. The Interplay name is used with the permission of the Interplay Entertainment Corp. which bears no responsibility for Avid products. All other trademarks are the property of their respective owners. Product features, specifications, system requirements and availability are subject to change without notice.

PRESS CONTACT: 
Sara Griggs
Avid 
sara.griggs@avid.com 
310-907-6909
Friday, October 30th, 2015 Uncategorized Comments Off on (AVID) Everywhere for Audio Continues to Deliver Groundbreaking Innovations

(OASM) receives order of $7.5 million in end-user value for the Russian market

Interest continues to rise as Oasmia receives a new order for its lead oncology product Paclical(r) through the company’s commercial partner Pharmasyntez

NEW YORK, Oct. 30, 2015  — Oasmia Pharmaceutical AB (NASDAQ:OASM) – a developer of a new generation of drugs within human and veterinary oncology, announced today that it its distribution partner in Russia and the Commonwealth of Independent States, CIS, Pharmasyntez, has placed its second order for Paclical, Oasmia’s lead cancer product for an end user sale value of $7.5 million. The announcement comes on the heels of the first order to the Russia market for $1.5 million in end-user value, totaling an end-user sales value of over $9 million USD in commercial orders within one week.

“We are thrilled that Paclical has been so well received in Russia and CIS,” said Julian Aleksov, Executive Chairman of Oasmia. “These positive initial orders are a reflection of the market’s confidence in the product. We are confident in imminent sales growth as the product continues to garner interest for its ability to enable higher doses, shorten infusion time, eliminate the need for pre-medication and improve the safety profile for patients compared to the available standard treatments.”

About Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB develops new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company’s product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ Stockholm (OASM:SE), the Frankfurt Stock Exchange (OMAX:GR, ISIN SE0000722365) and on NASDAQ US (OASM:US).

About Pharmasyntez

The company was founded in 1997 and is now one of the ten biggest pharmaceutical companies in Russia. Pharmasyntez specializes in drugs against tuberculosis, but also manufactures antibiotics and solutions for infusions. Furthermore, the company cooperates with a number of leading institutes and universities in Russia.

About Paclical

Paclical is a water-soluble formulation of paclitaxel and Oasmias patented excipient, XR-17. Paclitaxel is one of the most widely used anti-cancer substances and is included in the standard treatment of a variety of cancers such as lung cancer, breast cancer and ovarian cancer. Paclical(r) consists of a freeze dried powder dissolved in conventional solution for infusion. In April 2015, Paclical received a marketing authorization for treatment of ovarian cancer in the Russian Federation.

Julian Aleksov, Executive Chairman,
Tel: +46 18 50 54 40
E-mail: julian.aleksov@oasmia.com

Anders Lundin, Chief Financial Officer
Mobile: +46 70 20 96 300
E-mail: anders.lundin@oasmia.com

For media inquiries, please contact:
Eric Fischgrund
FischTank Marketing and PR
Tel: 646 699 1414
E-mail: eric@fischtankpr.com

Friday, October 30th, 2015 Uncategorized Comments Off on (OASM) receives order of $7.5 million in end-user value for the Russian market

(PRXI) Announces Shareholder Approval of Merger With Dinoking Tech Inc.

ATLANTA, Oct. 30, 2015  — Premier Exhibitions, Inc. (NASDAQ:PRXI) “Premier” or the “Company”, a leading presenter of museum-quality touring exhibitions around the world, announced that, at a special meeting of shareholders on October 29, 2015, its shareholders voted in favor of all of the proposals presented to the meeting and necessary to approve the acquisition by the Company of the outstanding shares of Dinoking Tech Inc. (“Dinoking”) through the issuance of Premier shares or shares exchangeable for Premier shares. The merger transaction is expected to formally occur in the next few days.

In addition, Premier shareholders approved the issuance of Premier shares by the Company in consideration of any future contingent payments owing to Dinoking shareholders (with a maximum cash value of up to US$8.6 million) if certain milestones are reached by Dinoking. The Premier common shares will be issued under and in accordance with the Merger Agreement or the Future Contingency Payments Agreement, as applicable, each dated as of April 2, 2015.

Pursuant to the Merger Agreement, upon the closing of the merger of the Company and Dinoking, the Company’s board of directors will appoint Mr. Daoping Bao as the Executive Chairman of the Board, President and Chief Executive Officer of the Company.

About Premier Exhibitions, Inc.:

Premier Exhibitions, Inc. (Nasdaq:PRXI), located in Atlanta, GA, is a major provider of museum quality exhibitions throughout the world and a recognized leader in developing and displaying unique exhibitions for education and entertainment. The Company’s exhibitions present unique opportunities to experience compelling stories using authentic objects and artifacts in diverse environments. Exhibitions are presented in museums, exhibition centers and other entertainment venues. Additional information about Premier Exhibitions, Inc. is available at www.prxi.com.

About Dinoking Tech Inc.:

Dinoking Tech Inc. is a holding company operating under the name Dinosaurs Unearthed. Dinosaurs Unearthed, located in Richmond, British Columbia, Canada, is an industry-leading traveling exhibition company with a range of exhibition products designed and developed by its creative and innovative team of experts and scientific advisors. Exhibition products include Dinosaurs Unearthed, Dinosaurs Alive!, Extreme Dinosaurs, Xtreme BUGS!, and Creatures of the Deep. The company creates outstanding immersive guest experiences that are engaging, entertaining and grounded in current science. Since the company’s launch in 2007, exhibitions have opened throughout North America, Australia, Asia, Europe and the Middle East, inspiring millions of guests in museums, science centers, zoos, amusement parks and other unique venues. Additional information about Dinosaurs Unearthed is available at www.dinosaursunearthed.com.

Forward Looking Statements

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve certain risks and uncertainties. The actual results or outcomes of Premier Exhibitions, Inc. may differ materially from those anticipated. Although Premier Exhibitions, Inc. believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any such assumptions could prove to be inaccurate. Therefore, Premier Exhibitions, Inc. can provide no assurance that any of the forward-looking statements contained in this press release will prove to be accurate.

In light of the significant uncertainties and risks inherent in the forward-looking statements included in this press release, such information should not be regarded as a representation by Premier Exhibitions, Inc. that its objectives or plans will be achieved. Included in these uncertainties and risks are, among other things, fluctuations in operating results, general economic conditions, uncertainty regarding the results of certain legal proceedings and competition. Forward-looking statements consist of statements other than a recitation of historical fact and can be identified by the use of forward-looking terminology such as “may,” “intend,” “expect,” “will,” “anticipate,” “estimate” or “continue” or the negatives thereof or other variations thereon or comparable terminology. Because they are forward-looking, such statements should be evaluated in light of important risk factors and uncertainties. These risk factors and uncertainties are more fully described in Premier Exhibitions, Inc. most recent Annual and Quarterly Reports filed with the Securities and Exchange Commission, including under the heading entitled “Risk Factors.” Premier Exhibitions, Inc. does not undertake an obligation to update publicly any of its forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

CONTACT: Investor Contact:

         Michael J. Little
         Interim President and Chief Executive Officer,
         Chief Financial and Chief Operating Officer
         (404) 842-2600
         mlittle@prxi.com
Friday, October 30th, 2015 Uncategorized Comments Off on (PRXI) Announces Shareholder Approval of Merger With Dinoking Tech Inc.

(SZYM) & (BG) Expand Joint Venture

Global Teams to Jointly Commercialize Breakthrough Algae Oils and Ingredients for Sustainable and Healthier Foods

Solazyme (Nasdaq:SZYM) (“Solazyme”), a pioneer in microalgae innovation and Bunge Limited (NYSE:BG) (“Bunge”), a leading global agribusiness and food company, today announced they have agreed to expand their joint venture (“JV”) to include a focus on food. The expansion includes a range of breakthrough oils for food and products for animal nutrition. The expanded joint venture will build on Solazyme’s ground-breaking microalgae innovation platform, and on Bunge’s global leadership in food and ingredients, including vegetable oils. As part of the JV expansion, the partners also entered into an agreement to expand their co-funded research programs to include new unique products in nutrition and specialty fats. Manufacturing will take place in the JV’s world-class fully operational facility in São Paulo state, Brazil, site of the largest aerobic fermentation vessels in the world.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151030005138/en/

As part of the agreement, AlgaWise™ Ultra Omega-9 Algae Oil, AlgaWise™ High Stability Algae Oil and AlgaWise™ Algae Butter structuring fats will be marketed by Bunge’s established global food oil sales and applications team, who bring strong expertise and a global footprint. In addition, Bunge will handle oil processing and supply chain aspects of commercialization.

AlgaWise™ food oils to sustainably advance human nutrition

The expanded JV will manufacture and commercialize a range of new to the world, highly differentiated products, each providing breakthrough solutions to meet major needs in the food industry:

  • AlgaWise™ Ultra Omega-9 Algae Oil is a clean tasting oil with the highest level of monounsaturated fats (>90%) on the market and the lowest level of saturated fat of any food oil (<4%). This oil is ideal for meeting market demand for healthier alternatives to saturated fat oils, providing shelf-life stability and excellent culinary performance with one of the highest smoke points available.
  • AlgaWise™ High Stability Algae Oil delivers step change performance with one of the highest stabilities of any oil on the market, over 87% monounsaturated fatty acids and only 2% polyunsaturates, less than any other food oil. High Stability Algae Oil drives unprecedented oxidative stability with zero trans-fat per serving. With an exceptionally neutral flavor and high stability under varying conditions, this is a high performance oil that works well in industrial frying, spraying/coating, pan spraying and blending. It can enable food manufacturers to remove added preservatives in everyday favorite foods such as dressings and mayonnaise, achieving cleaner labels with fewer ingredients, as well as completely removing partially hydrogenated vegetable oils.
  • AlgaWise™ Algae Butter has a composition and functionality mirroring high value structuring fats such as shea stearin, with a high proportion of stearic-oleic-stearic triglycerides (~70%). This unique oil can be used in a wide range of products. It is expected to have significant value in confectionery based on its reliable, scalable and sustainable supply, as well as offering a better performing alternative for bakery, confectionary, spreads and other applications. The product is expected to be available for the U.S. market in 2016.

Soren Schroder, CEO, Bunge Limited, said, “Strengthening our relationship with Solazyme gives us a differentiated product offering in specialty food and feed ingredients. With Solazyme, we believe we are bringing true innovation and enhanced sustainability to the global food industry. These healthier algae products have tremendous potential to make a positive impact in nutrition and functionality for our customers around the globe, and we’re excited about the potential to broadly commercialize them.”

“Bunge is a leading global agribusiness and food company, and has been a strong long-term partner who shares our vision. Not only do they have fantastic capabilities but they also understand the value of both our ingredients and our underlying technology platform. We are very happy to be deepening and expanding the partnership to include Bunge’s global food sales, marketing, and applications strength and presence. This will further enable our algae-based food ingredients to bring great benefits to people and our planet,” commented Jonathan Wolfson, Solazyme’s CEO.

Sustainability

The products in the scope of the JV will be produced at the joint venture’s manufacturing facility in Brazil adjacent to Bunge’s Moema sugarcane mill. The oils produced have one of the lowest carbon and water footprints of any broadly available vegetable oils and achieve substantially higher oil yields per acre than those of most oilseed crops.

History of collaboration

Today’s announcement follows a history of collaboration between the two companies, beginning with Bunge’s 2010 equity investment in Solazyme, followed by the original Joint Venture agreement in April 2012 that established the production facility at Moema as well as multiple jointly funded development programs over that period of time.

About Solazyme, Inc.

Solazyme, Inc. develops and sells innovative, sustainable, high-performance oils and ingredients that are better for people and better for the planet. Starting with microalgae, one of the world’s original sources of oil, Solazyme creates renewable oils and ingredients that serve as the foundation for creating healthier foods; high-performance industrial products; unique home and personal care solutions; and more sustainable fuels. Headquartered in South San Francisco, Solazyme’s mission is to solve some of the world’s biggest problems with one of the world’s smallest and earliest life forms: microalgae. For additional information, please visit Solazyme’s website at www.solazyme.com.

Solazyme®, AlgaWise™, and the Solazyme logo are trademarks of Solazyme, Inc.

About Bunge

Bunge Limited (www.bunge.com, NYSE: BG) is a leading global agribusiness and food company operating in over 40 countries with approximately 35,000 employees. Bunge buys, sells, stores and transports oilseeds and grains to serve customers worldwide; processes oilseeds to make protein meal for animal feed and edible oil products for commercial customers and consumers; produces sugar and ethanol from sugarcane; mills wheat, corn and rice to make ingredients used by food companies; and sells fertilizer in South America. Founded in 1818, the company is headquartered in White Plains, New York.

Forward Looking Statements

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements that involve risks and uncertainties concerning: market acceptance of products; and the ability to maintain relationships with partners. When used in this press release, the words “will”, “expects”, “intends” and other similar expressions and any other statements that are not historical facts are intended to identify those assertions as forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any such statement may be influenced by a variety of factors, many of which are beyond the control of the companies, that could cause actual outcomes and results to be materially different from those projected, described, expressed or implied in this press release due to a number of risks and uncertainties. Potential risks and uncertainties include, among others: limited operating history; limited history commercializing products; implementation risk in deploying new technologies; limited experience in ramping up and operating commercial manufacturing facilities; delays related to ramp-up of production facilities; and availability of consistent, reliable power and steam. Accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition.

In addition, please refer to the documents that Solazyme, Inc. files with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q, as updated from time to time, for a discussion of these and other risks. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. Solazyme is not under any duty to update any of the information in this press release.

Cautionary Statement Concerning Forward-Looking Statements

This press release contains both historical and forward-looking statements. All statements, other than statements of historical fact are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are not based on historical facts, but rather reflect our current expectations and projections about our future results, performance, prospects and opportunities. We have tried to identify these forward-looking statements by using words including “may,” “will,” “should,” “could,” “expect,” “anticipate,” “believe,” “plan,” “intend,” “estimate,” “continue” and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and other factors that could cause our actual results, performance, prospects or opportunities to differ materially from those expressed in, or implied by, these forward-looking statements. The following important factors, among others, could affect our business and financial performance: industry conditions, including fluctuations in supply, demand and prices for agricultural commodities and other raw materials and products used in our business; fluctuations in energy and freight costs and competitive developments in our industries; the effects of weather conditions and the outbreak of crop and animal disease on our business; global and regional agricultural, economic, financial and commodities market, political, social and health conditions; the outcome of pending regulatory and legal proceedings; our ability to complete, integrate and benefit from acquisitions, dispositions, joint ventures and strategic alliances; our ability to achieve the efficiencies, savings and other benefits anticipated from our cost reduction, margin improvement and other business optimization initiatives; changes in government policies, laws and regulations affecting our business, including agricultural and trade policies, tax regulations and biofuels legislation; and other factors affecting our business generally. The forward-looking statements included in this release are made only as of the date of this release, and except as otherwise required by federal securities law, we do not have any obligation to publicly update or revise any forward-looking statements to reflect subsequent events or circumstances.

 

Solazyme Contacts:
Solazyme, Inc.
Genet Garamendi
Corporate Communications
press@solazyme.com
or
Brainerd Communicators, Inc.
Mike Smargiassi, 212-986-6667
smarg@braincomm.com
Brad Edwards, 212-986-6667
edwards@braincomm.com
or
Bunge Contacts:
Bunge Limited
Investor Contact:
Mark Haden, 914-684-3398
mark.haden@bunge.com
Media Contact:
Susan Burns, 914-684-3246
susan.burns@bunge.com

Friday, October 30th, 2015 Uncategorized Comments Off on (SZYM) & (BG) Expand Joint Venture

(LFVN) Launches TrueScience Micro Lift Serum

Company Expands Its Revolutionary TrueScience™ Skin Care System

SALT LAKE CITY, Oct. 29, 2015  — LifeVantage Corporation (Nasdaq:LFVN), has launched TrueScience Micro Lift Serum for immediate distribution in the United States. The TrueScience Micro Lift Serum is a natural way to instantly diminish the look of crow’s feet, baggy skin, and dark circles around the eyes. In as little as 3 minutes, it visibly tightens, smooths, and firms the skin around the eyes, quickly restoring a youthful looking radiance without sacrificing long-term skin health. The TrueScience Micro Lift Serum pairs with the revolutionary TrueScience™ Skin Care system and is only available from LifeVantage.

“Customers today expect instant results from the products they use,” said LifeVantage President and Chief Executive Officer Darren Jansen. “ Our TrueScience Micro Lift Serum is in alignment with our strategy of offering demonstrable and effective products. It’s the ideal companion to our TrueScience skin care system that uses proven ingredients to take years off of your appearance and now provides instant and long term anti-aging benefits.”

CLICK HERE to see why we are so excited about the newest addition to TrueScience™ skin care system.

About LifeVantage Corporation
LifeVantage Corporation (Nasdaq:LFVN), is a science based network marketing company dedicated to visionary science that looks to transform health, wellness and anti-aging internally and externally at the cellular level. The company is the maker of Protandim®, the Nrf2 Synergizer® patented dietary supplement, the TrueScience™ Anti-Aging Skin Care system, Canine Health, and the AXIO™ energy product line.  LifeVantage was founded in 2003 and is headquartered in Salt Lake City, Utah.

Forward Looking Statements
This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as “believe”, “hopes”, “intends”, “estimates”, “expects”, “projects”, “plans”, “anticipates”, “look forward to”, “goal”, “ideal fit”, and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Examples of forward-looking statements include, but are not limited to, statements we make regarding our leadership in the global market, future growth and financial performance. Such forward-looking statements are not guarantees of performance and the Company’s actual results could differ materially from those contained in such statements. These forward-looking statements are based on the Company’s current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company’s actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others, those discussed in greater detail in the Company’s Annual Report on Form 10-K and the Company’s Quarterly Report on Form 10-Q under the caption “Risk Factors,” and in other documents filed by the Company from time to time with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law.

Company Relations Contact: 
John Genna (801) 432-9172
Vice President of Communications & 
Corporate Partnerships

Investor Relations Contact:
Cindy England (801) 432-9036
Director of Investor Relations
-or-
John Mills (646) 277-1254
Partner, ICR INC
Thursday, October 29th, 2015 Uncategorized Comments Off on (LFVN) Launches TrueScience Micro Lift Serum

(NYMX) Reports Results of Prospective Cross-Over Study of Fexapotide

HASBROUCK HEIGHTS, N.J., Oct. 29, 2015  — Nymox Pharmaceutical Corporation (NASDAQ:NYMX) reported today that long-term randomized cross-over data from the Company’s  trial of fexapotide triflutate for low grade localized prostate cancer has shown statistical significance in efficacy compared to controls. The study results indicate that randomized control subjects who subsequently switched to fexapotide had long-term outcomes significantly superior to control patients who did not change (cross-over) to fexapotide treatment.

These results are the initial 18 month follow-up results for the fexapotide trial for prostate cancer to be reported. The cross-over study arm of NX03-0040 consisted of 35 subjects. Based on biopsy progression the proportion of patients who progressed on biopsy and required biopsy progression-related surgery or radiotherapy in the cross-over group (0%) at 18 months was significantly less than in the control group (p<.03).

The cross-over group patients received randomized fexapotide 15 mg or 2.5 mg in a single treatment targeted toward the positive baseline cancer focus identified in initial positive biopsies. There were no cases in either of the 2 fexapotide dosage level treatment groups with biopsy progression at 18 months (p<.03).

In addition to the positive clinical progression results, the primary endpoint of the study (re-biopsy absence of tumor in the initially positive biopsy baseline area of the prostate) also reached statistical significance (p<.03) in the cross-over study. At the 18 month assessments, the post-treatment biopsy taken from the treated area of the prostate which was initially positive at baseline, showed absence of tumor (tumor presence in re-biopsy of baseline positive focus n=0) in the cross-over treated patients, which was statistically significant compared to controls (p<.03).

The Company expects to report results from its long-term NX03-0040 low grade localized prostate cancer study in the fourth quarter.

One of the major problems with current prostate treatments for localized prostate cancer (radical prostatectomy, external beam radiation, or brachytherapy) is the relatively high incidence of reported sexual dysfunction post-treatment. In 9 studies, NX-1207 treatment has been shown to have no significant adverse effect post-treatment on sexual function or testosterone levels.

For more information please contact info@nymox.com or 800-936-9669.

Forward Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox’s regulatory filings, Nymox’s substantial dependence on fexapotide, Nymox’s commercialization plans and efforts and other matters that could affect the availability or commercial potential of fexapotide. Nymox undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox’s current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2014, and its Quarterly Reports.

 

Contact:
Paul Averback
Nymox Pharmaceutical Corporation
800-93NYMOX
www.nymox.com
Thursday, October 29th, 2015 Uncategorized Comments Off on (NYMX) Reports Results of Prospective Cross-Over Study of Fexapotide

(OHGI) Aishuo App Breaks 10 Million Downloads in China in First Eight Months

App on Target to Exceed 2-Year Goal of 15 Million Subscribers

LIMERICK, IRELAND–(Oct 29, 2015) – One Horizon Group, Inc. (NASDAQ: OHGI) (“One Horizon,” “We” or the “Company”), which operates its own Chinese retail VoIP service, branded Aishuo, and develops and licenses a bandwidth efficient mobile voice over Internet Protocol (“VoIP”) platform for smartphones, announced today that its Aishuo App has achieved over 10 million downloads since its launch in late February 2015, and is well on the way to reaching its 24 month stated goal of 15 million users.

One Horizon believes the number of downloads indicates the rapid growth of Aishuo network and possibility of it becoming a base model communication platform for Chinese users because of its technology advancements and underlying value.

Mobile VoIP services are heavily geared towards free calls for users. Aishuo not only offers free app-to-app calls but also allows its subscribers to purchase call credit to call landlines or mobile phones, local or internationally. Its upgraded solution offers seamless 3G to Wi-Fi calls to enable users to stay connected in walk and talk. It also allows users to place low cost calls while on the move by delivering a ten times less bandwidth VoIP call over wireless networks such as 3G and 4G. The users of Aishuo can save on data charges where applied, while continuing to have higher call quality in app (or) to landline/mobile phone.

One Horizon Group CEO Brian Collins noted, “At this very early stage in our lifecycle, we are demonstrating that there is a sustainable, expanding business model in deploying a smartphone app to people that want low priced mobile VoIP calls using our unique, and patent protected, high quality voice technology. We are also encouraged to see early revenues in a space which is typically dominated by free app-to-app calls. We provide all the free services as well, but also deliver a way to drive revenues in ‘low cost calling while mobile’ for when we need to call someone that is not another smartphone app user. We look forward to reporting our final revenue numbers for the quarter in November and Aishuo’s effect on our overall bottom line.”

Aishuo supports all major Chinese mobile payment platforms including China UnionPay, Apple In-App Purchases, Alibaba’s Alipay and Tencent’s WeChat Wallet providing subscribers with convenient options to purchase call credit.

Downloads of the Aishuo retail App are available on the Apple iTunes and 20 Chinese Android App stores including Baidu, Tencent, 360.CN and Xiaomi. The Aishuo rollout to Chinese smartphone users commenced in late February 2015 and the Company is seeking to acquire 15 million new subscribers over a two-year period with a view to leverage this user base to achieve industry average revenues per user (ARPU) for similar social media, mobile advertising and mobile VoIP apps.

Aishuo is available as a FREE download in over 25 App stores including Apple iTunes, Baidu’s 91.com and Baidu.com, the Tencent App store MyApp.com, 360 Qihoo store 360.cn and the ever growing Xiaomi store mi.com.

About One Horizon Group, Inc.
One Horizon Group Inc.’s business is to optimize communications over the Internet through its wholly owned subsidiary, Horizon Globex GmbH, Zug, which develops and markets one of the world’s most bandwidth-efficient mobile voice over Internet Protocol (VoIP) platforms for smartphones, and also offers a range of other optimized data Applications including messaging and mobile advertising. The company controls and operates the Aishuo mobile VoIP service in China. Horizon Globex GmbH is an ISO 9001 and ISO 20000-1 certified company. The Company has operations in Ireland, Switzerland, the United Kingdom, China, India, Singapore and Hong Kong. For more information on the Company, its products and services, please visit http://www.onehorizongroup.com

Safe Harbor Statement
This news release may contain “forward-looking” statements. These forward-looking statements are only predictions and are subject to certain risks, uncertainties and assumptions that could cause actual results to differ from those in the forward looking-statements. Potential risks and uncertainties include such factors as uncertainty of consumer demand for the Company’s products, as well as additional risks and uncertainties that are identified and described in Company’s SEC reports. Actual results may differ materially from the forward-looking statements in this press release. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company does not undertake, and it specifically disclaims, any obligation to update any forward-looking statements to reflect occurrences, developments, events or circumstances after the date of such statement.

** News and content distribution provided by 1800pr.com

Contact:
Ted Haberfield
MZ Group | President – MZ North America
Direct: 760-755-2716
Mobile: 858-204-5055
thaberfield@mzgroup.us
www.mzgroup.us

Thursday, October 29th, 2015 Uncategorized Comments Off on (OHGI) Aishuo App Breaks 10 Million Downloads in China in First Eight Months

(RVNC) Reports Positive 6-Month Duration in BELMONT Study

Phase 2 Active Comparator, Double-Blinded, Placebo-Controlled, Multi-Center Trial of RT002 Injectable Botulinum Toxin Type A for the Treatment of Glabellar Lines

– 6-month duration of effect is statistically significant compared to BOTOX® Cosmetic –

– All dose levels of RT002 achieved highly statistically significant, investigator-reported efficacy compared to placebo at Week 4 –

– All dose levels of RT002 appear to be safe and well tolerated –

– Company to host conference call at 8:00 am ET today –

NEWARK, Calif., Oct. 29, 2015  — Revance Therapeutics, Inc. (NASDAQ:RVNC), announced positive 24-week results today from its multi-center BELMONT Phase 2 active comparator study of injectable RT002. The ongoing study for the treatment of glabellar lines in 268 subjects compared the safety, efficacy and duration of effect of three doses of RT002 against placebo, and current market leader, BOTOX Cosmetic/ VISTABEL®.  The topline interim data showed that RT002– a botulinum toxin type A investigational drug product candidate for injection– achieved its primary efficacy measurement for all three doses at 4 weeks. The study demonstrated 6-month RT002 median duration of effect based upon at least 1-point improvement in glabellar lines at maximum frown on the Investigator Global Assessment-Facial Wrinkle Severity (IGA-FWS) scale.

Key interim results of the BELMONT trial

  • The 4 week primary efficacy measurement of at least 1-point improvement in frown lines based on the IGA-FWS scale for all three doses (20 Units, 40 Units and 60 Units) of RT002 was highly statistically significant (p < 0.001) as compared to placebo for all three doses.
  • All doses of RT002 achieved a 100 percent response rate of at least 1-point improvement in frown lines, based on the IGA-FWS scale at 4 weeks versus a 95 percent response rate for BOTOX Cosmetic.
  • RT002 efficacy showed a dose response. RT002 40U was statistically significant to BOTOX Cosmetic on all three responder definitions for the IGA-FWS median duration of effect. On the IGA-FWS duration of response.RT002 demonstrated a 23.6 week median duration versus BOTOX Cosmetic with an 18.8 week median duration (p=0.020).
  • More than twice as many RT002 40U and 60U subjects in the study maintained none or mild wrinkles on the IGA-FWS scale as compared to BOTOX Cosmetic at Week 16 (p≤0.002).
  • Subject-reported outcomes were consistent with investigator findings of duration and efficacy of RT002.
  • Across all cohorts, RT002 appeared to be generally safe and well-tolerated. Adverse events were generally mild, localized and transient. For RT002 20U and 40U, no subjects experienced ptosis (eyelid droop). There were no serious adverse events or evidence of any systemic exposure at any of the three doses evaluated.

“The BELMONT study, using some of the top botulinum toxin injectors, was designed to further demonstrate the effectiveness and duration of RT002 versus BOTOX Cosmetic, the current market leader. The interim results are compelling,” said Dan Browne, President and Chief Executive Officer at Revance. “The results clearly support that 40U is the right dose to take forward. We plan to report BELMONT’s final study results and to conduct an End-of-Phase 2 meeting with the FDA in the first half of next year. We expect to begin Phase 3 clinical studies in the second half of 2016. Assuming the duration observed in our Phase 3 studies is consistent with the results reported today, we believe the collective data should support a 6-month duration label.”

“Botulinum toxin use for frown lines is one of the most popular procedures requested by patients in my practice,” said Jean D. Carruthers, MD, Clinical Professor, at University of British Columbia, Medical Director at Jean Carruthers Cosmetic Surgery Inc., a lead investigator for the RT002 BELMONT trial, and one of the world’s foremost leaders in aesthetic botulinum toxin use. “With BELMONT, Revance has done something that has never been done before in a neurotoxin Phase 2 clinical program in terms of demonstrating superior duration of effect in an active comparator study. The 100 percent achievement of at least a 1-point improvement on the Facial Wrinkle Severity Scale seen as early as two weeks in all dose groups is impressive. The 6-month duration makes this a likely game changer in our aesthetic practices. Currently many of my patients come in year after year on a quarterly basis for botulinum toxin injections. With RT002 they could get their botulinum toxin treatments on a bi-annual basis, which conveniently coincides with a large percentage of my patients who receive fillers or other treatments for pan facial uses.”

“We believe multiple aesthetic and therapeutic indications within the estimated $3 billion global neurotoxin market may benefit from RT002’s solid safety profile and sustained duration, including muscle movement disorders and pain management,” Browne continued. “Our botulinum toxin Type A, combined with our proprietary TransMTS® peptide technology, provides a significant scientific advancement in neurotoxin therapy that has the potential to meaningfully expand the injectable market.”

BELMONT Phase 2 Study Design

BELMONT is a Phase 2, randomized, double-blind, dose-ranging, active comparator and placebo-controlled, multi-center study conducted at key sites in Canada. The study evaluates the safety, efficacy and duration of three doses of RT002 (RTT150 (Botulinum Toxin Type A) for Injection, 20U, 40U or 60U), compared to the labeled dose of the current market leader BOTOX Cosmetic 20U (or VISTABEL as trademarked in Canada) and a placebo control in treating glabellar lines.   The BELMONT study enrolled 268 subjects with moderate to severe glabellar lines during maximum frown. The primary efficacy measurements for the study, consistent with the BOTOX Cosmetic label, are the investigator’s assessment of glabellar line severity at maximum frown (IGA-FWS) and median duration of effect from the date of treatment to when a subject reverts back to baseline severity. Subjects in the BELMONT study were randomized equally across five study groups receiving one of three doses of RT002, the active comparator or placebo. The results today are based on the interim 24-week results, and the trial continues to follow a subset of subjects for up to 36 weeks or until they return to baseline. Additional information about the trial can be found at www.clinicaltrials.gov, Clinical trial identifier NCT02303002.

Conference Call

Revance management will host a conference call and webcast today at 8:00 am ET. Individuals interested in listening to the conference call today, October 29, at 5:00am PT/8:00 am ET may do so by dialing (855) 453-3827 for domestic callers, or (484) 756-4301 for international callers and reference conference ID: 59573766; or from the webcast link in the investor relations section of the Company’s website at: www.revance.com.

A replay of the call will be available beginning October 29, 2015 at 8:00 am PT/11:00 am ET through midnight on October 29, 2015. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 59573766. The webcast will be available in the investor relations section on the Company’s website for 30 days following the completion of the call.

About Glabellar Lines

The glabella is the skin between the eyebrows and above the nose. Glabellar lines (often called “frown lines”) are those vertical lines that develop between the eyebrows and may appear as a single vertical line or as two or more lines and may also appear angled towards the inner corners of the eyebrows.  When you frown, the muscles of the lower forehead contract in a downward direction causing the skin between the eyebrows to crease. Lines are formed by the repeated action of frowning due to the lack of elasticity in the skin. Age, sun exposure, and genetics are contributing factors.  Botulinum toxin is used to block the nerve impulses, temporarily paralyzing the muscles that cause the frown lines, giving the skin a smoother, more refreshed appearance.

Based on data from UBS Global Research, the global market for aesthetic treatments with neurotoxins represented about a $1.4 million market in 2014 and according to the American Society for Aesthetic Plastic Surgery, botulinum toxin treatment is the number one nonsurgical cosmetic procedure in the U.S. glabellar line treatment represents the largest segment of that market.

About RT002

Investigational drug product candidate RT002, RTT150 (Botulinum Toxin Type A) for Injection, combines Revance’s proprietary, pure 150kD botulinum toxin type A molecule, without any accessory proteins or animal derived components, with Revance’s patented TransMTS® peptide technology. RT002 is designed to offer targeted delivery to the intended treatment sites, while reducing its spread beyond the site of local injection. RT002 is in clinical development for the treatment of glabellar (frown) lines and for cervical dystonia, and has the potential to address additional therapeutic indications in movement disorders, pain, urology, ophthalmology, and other potential uses where targeted delivery is required or long duration is desired.

About Revance Therapeutics, Inc.

Revance is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. The company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented TransMTS® peptide delivery system to address unmet needs in the large and growing neurotoxin markets. Revance’s proprietary TransMTS technology enables delivery of botulinum toxin A through two novel drug product candidates, a needle-free topical form and an injectable form that may localize the drug to the site of injection, resulting in a targeted and potentially long-lasting delivery.  Revance is pursuing clinical development for drug product candidates RT001 topical and RT002 injectable in a broad spectrum of aesthetic and therapeutic indications. The company holds worldwide rights for all indications of RT001, RT002 and the TransMTS technology platform. More information on Revance Therapeutics can be found at www.revance.com.

“Revance Therapeutics”, TransMTS® and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

*BOTOX® and VISTABEL® are registered trademarks of Allergan, Inc.

Forward-Looking Statements

This press release contains forward-looking statements, including statements about our RT002 investigational drug product candidate, including but not limited to, statements about the features and benefits, business strategy, goals and market for our anticipated products, approval, plans and prospects and statements about potential benefits of our drug product candidates and our technologies.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties include, but are not limited to: the outcome, cost and timing of our product development activities and clinical trials; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; our ability to obtain and maintain regulatory approval of our drug product candidates; our ability to obtain funding for our operations; our plans to research, develop and commercialize our drug product candidates; our ability to achieve market acceptance of our drug product candidates; unanticipated costs or delays in research, development and commercialization efforts; the applicability of clinical study results to actual outcomes; the size and growth potential of the markets for our drug product candidates; our ability to successfully commercialize our drug product candidates and the timing of commercialization activities; the rate and degree of market acceptance of our drug product candidates; our ability to develop sales and marketing capabilities; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for financing; our ability to continue obtaining and maintaining intellectual property protection for our drug product candidates; and other risks. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Revance’s periodic filings with the Securities and Exchange Commission (the “SEC”), including factors described in the section entitled “Risk Factors” section of our quarterly report on Form 10-Q filed August 7, 2015. These forward-looking statements speak only as of the date hereof. Revance disclaims any obligation to update these forward-looking statements.

CONTACT: Investors:
         Revance Therapeutics
         Jeanie Herbert
         (714) 325-3584
         jherbert@revance.com

         Westwicke Partners
         Leigh Salvo
         (415) 513-1281
         leigh.salvo@westwicke.com

         Trade Media:
         Nadine Tosk
         (504) 453-8344
         nadinepr@gmail.com
Thursday, October 29th, 2015 Uncategorized Comments Off on (RVNC) Reports Positive 6-Month Duration in BELMONT Study

(RKDA) Field Trials Show Average Yield Increases of 19 Percent

– Improved Rice Will Enhance Farm Economics, Food Security and Sustainable Agriculture in the Developing World –

Two years of field trials in Africa with leading lines of Nitrogen Use Efficient (NUE) rice have demonstrated an average yield increase of 19 percent over the conventional control lines.

These results were reported jointly today by Arcadia Biosciences, Inc., an agricultural technology company, the Council for Scientific and Industrial Research of Ghana’s Crops Research Institute (CSIR-CRI), the National Agricultural Research Organisation (NARO) of Uganda, and the African Agricultural Technology Foundation (AATF).

CSIR-CRI and NARO have been testing the new rice lines using Arcadia’s NUE trait at two field research locations in Kumasi, Ghana and Namulonge, Uganda.

In the 2014 and 2015 field trials, eight out of the 15 NUE rice lines out-yielded the conventional control lines under rain-fed upland conditions applied with various nitrogen fertilizer rates. The leading NUE rice line showed an average grain yield increase of 19 percent in multiple field trials. At nitrogen rates of 30, 60 and 90 kg per hectare, the yield increase of the leading NUE rice line was 25 percent, 14 percent and 19 percent, respectively, compared with the control lines.

The African field trial results build on results from field trials carried out by the International Center for Tropical Agriculture (CIAT) in Colombia. In the CIAT trials, four years of testing at two locations demonstrated an average yield increase from the NUE rice lines of 30 percent over the control rice lines.

“Arcadia’s NUE trait has consistently shown double-digit yield increases in all major types of rice grown globally,” said Eric Rey, president and CEO of Arcadia. “These results have been achieved in multiple geographies, over many seasons, and under a variety of growing conditions and nitrogen application rates. Our NUE trait has the potential to deliver significant value to farmers worldwide, enabling them to increase yield and farm revenue.”

Arcadia’s NUE trait was developed to help farmers increase crop yields per unit of applied nitrogen fertilizer. Nitrogen fertilizer is a key input to the global agricultural industry for increasing crop yield, but conventional crops typically use less than half of the nitrogen fertilizer applied. Much of the remainder moves through the soil and enters ground and surface water systems, or volatilizes into the air as a potent greenhouse gas. Arcadia’s NUE trait enables plants to produce higher yields while reducing the environmental footprint of agriculture.

Rice is the world’s most valuable crop, grown on more than 395 million acres globally with a harvest value of $429.3 billion in 2013. In Africa, rice is one of the most cultivated and important food crops. Most of Africa’s rice is produced and consumed by small-scale farmers who are often constrained by challenging environmental conditions, such as nutrient-deficient soil, drought and salinity. Soil nitrogen deficiencies, in particular, affect approximately 90 percent of African land used to grow rice and other crops.

Access to rice varieties that make better use of available nitrogen in soil and respond more effectively to small amounts of fertilizer can help alleviate these agricultural pressures on African farmers and can minimize the continent’s dependency on food imports. According to the United Nations Food and Agriculture Organization, farmers in Sub-Saharan Africa (SSA) produce about 22.5 million metric tons of rice annually, yet the continent imports more than 13 million metric tons, valued at approximately $7 billion.

The African NUE field trials are part of the NEWEST Rice project, a collaboration between Arcadia and the AATF, working with the United States Agency for International Development (USAID) and other organizations under the Feed the Future initiative to help bolster food security in Africa. NEWEST Rice is a triple-gene stack rice variety that combines Arcadia’s Nitrogen Use Efficiency, Water Use Efficiency and Salinity Tolerance traits, helping farmers maintain productivity under variable conditions. The multi-organizational effort leverages the experience of leading African agricultural research organizations, as well as technical expertise and a royalty-free license from Arcadia, to develop and test new rice lines. The Public Intellectual Property Resource for Agriculture provided access to enabling technologies, and CIAT conducted initial field evaluations of the most promising new rice lines.

About Arcadia Biosciences, Inc.

Based in Davis, Calif., with additional facilities in Seattle, Wash. and Phoenix, Ariz., Arcadia Biosciences (NASDAQ: RKDA) develops agricultural products that create added value for farmers while benefitting the environment and enhancing human health. Arcadia’s agronomic performance traits, including Nitrogen Use Efficiency, Water Use Efficiency, Salinity Tolerance, Heat Tolerance and Herbicide Tolerance, are all aimed at making agricultural production more economically efficient and environmentally sound. Arcadia’s nutrition traits and products are aimed at creating healthier ingredients and whole foods with lower production costs. The company was recently listed in the Global Cleantech 100 and was previously named one of MIT Technology Review’s 50 Smartest Companies. For more information, visit www.arcadiabio.com.

About The African Agricultural Technology Foundation (AATF)

The African Agricultural Technology Foundation (AATF) is a not-for-profit organization that facilitates and promotes public/private partnerships for the access and delivery of appropriate agricultural technologies with potential to increase the productivity of resource-poor smallholder farmers in Sub-Saharan Africa. For more information, visit www.aatf-africa.org.

About USAID

USAID is the lead U.S. Government agency that works to end extreme global poverty and enable resilient, democratic societies to realize their potential.

About Feed the Future

Feed the Future is the U.S. Government’s global hunger and food security initiative. With a focus on smallholder farmers, particularly women, Feed the Future supports partner countries in developing their agriculture sectors to spur economic growth and trade that increase incomes and reduce hunger, poverty and under nutrition. For more information, visit www.feedthefuture.gov.

About the CSIR-Crops Research Institute, Ghana

The mission of the Council for Scientific and Industrial Research of Ghana’s Crops Research Institute (CSIR-CRI) is to ensure high and sustainable crop productivity and food security through development and dissemination of environmentally sound technologies. CSIR-CRI has a broad research mandate covering all food and industrial crops. These include maize, rice, cowpea, soybean and groundnut. Others are cassava, yam, cocoyam, sweet potato, vegetables and fruit crops, plantain and bananas. For more information visit www.cropsresearch.org.

About the National Agricultural Research Organisation, Uganda

The National Agricultural Research Organisation (NARO) is the apex body for guidance and coordination of all agricultural research activities in the national agricultural research system in Uganda. Its goal is to enhance the contribution of agricultural research to sustainable agricultural productivity, economic growth, food security and poverty eradication through generation and dissemination of appropriate technologies, knowledge and information. For more information visit www.naro.go.ug.

About the Public Intellectual Property Resource for Agriculture

The Public Intellectual Property Resource for Agriculture (PIPRA) is a non–profit initiative which helps developing countries access new technologies by decreasing intellectual property barriers, improving commercialization strategies, and increasing technology transfer. PIPRA also helps public institutions more broadly by supporting them in getting their technological innovations to those who need it most. For more information visit www.pipra.org.

About the International Center for Tropical Agriculture (CIAT)

CIAT is an international agricultural research organization focused on eco-efficient agriculture that is, farming systems that better harness the available resources to be more competitive and to sustainably increase productivity, while leaving a smaller environmental footprint. CIAT significantly contributes to major global initiatives that seek to reduce rural poverty, strengthen food security, improve human health and nutrition, and sustainably manage natural resources throughout the developing world. For more information, visit www.ciatnews.cgiar.org.

Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to Arcadia’s NUE trait and the regulatory process for such trait. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: Arcadia’s and its partners’ ability to develop commercial products incorporating its traits, including the NUE trait, and complete the regulatory review process for such products; Arcadia’s compliance with laws and regulations that impact the company’s business, and changes to such laws and regulations; Arcadia’s future capital requirements and ability to satisfy its capital needs; and the other risks set forth in Arcadia’s filings with the Securities and Exchange Commission from time to time, including the risks set forth in Arcadia’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2015 and other filings. These forward-looking statements speak only as of the date hereof, and Arcadia Biosciences, Inc. disclaims any obligation to update these forward-looking statements.

 

Arcadia Biosciences, Inc.
Jeff Bergau
jeff.bergau@arcadiabio.com
+1-312-217-0419

Wednesday, October 28th, 2015 Uncategorized Comments Off on (RKDA) Field Trials Show Average Yield Increases of 19 Percent

(VTL) Closing of Public Offering of Common Stock

SAN DIEGO, Oct. 28, 2015  — Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing the ELAD® System, a cell-based therapy targeting the treatment of liver failure, today announced the closing of its previously announced underwritten public offering of 6,272,727 shares of its common stock at a price to the public of $5.50 per share, including 818,181 shares sold pursuant to the underwriter’s full exercise of its option to purchase additional shares. The aggregate gross proceeds from this offering were approximately $34.5 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Vital Therapies.

BofA Merrill Lynch acted as sole book-running manager for the offering.

The securities described above were offered pursuant to a shelf registration statement (File No. 333-204097) that was filed with the Securities and Exchange Commission on May 12, 2015, and that was declared effective on May 26, 2015. The final prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC. Copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained from BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, Email: dg.prospectus_requests@baml.com. An electronic copy of the final prospectus supplement and accompanying prospectus relating to the offering are available on the website of the Securities and Exchange Commission at www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of offers to buy any securities of Vital Therapies, and shall not constitute an offer, solicitation or sale of any security in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Vital Therapies, Inc.

Vital Therapies, Inc. is a biotherapeutic Company developing a cell-based therapy targeting the treatment of liver failure. The Company’s ELAD System is an extracorporeal human allogeneic cellular liver therapy. Vital Therapies, Inc. is based in San Diego, California. Vital Therapies® and ELAD® are trademarks of Vital Therapies, Inc.

CONTACT: Al Kildani
         Vice President, Investor Relations and Business Development
         Vital Therapies, Inc.
         858-673-6840
         akildani@vitaltherapies.com
Wednesday, October 28th, 2015 Uncategorized Comments Off on (VTL) Closing of Public Offering of Common Stock

(FATE) Strengthens IP Position With New U.S. Patent

Proprietary Pluripotent Cell Platform Has Broad Applicability for Development of Off-the-Shelf Cancer Immunotherapies

SAN DIEGO, Oct. 28, 2015  — Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders, announced today that the U.S. Patent and Trademark Office issued U.S. Patent No. 9,169,490 on October 27, 2015. The compositions described in the patent are foundational to the generation of induced pluripotent cells, which are a source of cells offering unique potential for off-the-shelf adoptive immunotherapy.

“Our novel induced pluripotent cell approach to cancer immunotherapy, which combines genetic engineering with rapid and efficient generation of immune cells, is designed to enable the unlimited production of engineered T cells and NK cells in a consistent, scalable and efficient manner,” said Scott Wolchko, Chief Operating and Financial Officer of Fate Therapeutics. “Supported by an intellectual property portfolio of over 30 issued patents and 60 pending applications, we believe we are uniquely positioned to develop and deliver on the potential for off-the-shelf cell-based cancer immunotherapies utilizing our proprietary pluripotent cell platform as an alternative approach to patient-sourced cells.”

The newly issued U.S. patent, which is owned by the Whitehead Institute for Biomedical Research and licensed exclusively to Fate Therapeutics for all therapeutic purposes, provides broad protection for cell compositions expressing a sufficient amount of octamer-binding transcription factor 4 (Oct4) to enable pluripotency. The production of Oct4 protein within a cell is a critical requirement to consistently and efficiently induce pluripotency. Fate Therapeutics is utilizing its novel platform to engineer the immunological properties of pluripotent cells, creating a continual source for the generation of engineered T- and NK-cell immunotherapeutics.

The first named inventor of this patent is Rudolf Jaenisch, M.D., a scientific founder of Fate Therapeutics. Dr. Jaenisch, a Professor of Biology at Massachusetts Institute of Technology, a founding member of the Whitehead Institute for Biomedical Research, and a member of the National Academy of Sciences, is a world-renowned scientist whose laboratory has made seminal contributions to the field of biological sciences, including understanding epigenetic regulation of gene expression in mammalian development and disease.

About Fate Therapeutics, Inc.

Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders. The Company’s cell-based product pipeline is comprised of off-the-shelf immuno-oncology therapeutics, including NK- and T-cell-based candidates derived from induced pluripotent cells, and immuno-regulatory therapeutics, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing auto-reactive T cells of patients with auto-immune disorders. Its adoptive cell therapy candidates are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the breadth and strength of the Company’s intellectual property portfolio, the therapeutic potential of programmed cellular immunotherapeutics, and the Company’s plans and ability to develop programmed cellular immunotherapeutics, including off-the-shelf NK- and T-cell-based cancer immunotherapeutics derived from induced pluripotent cells. These and any other forward-looking statements in this release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk of cessation or delay of planned research and development activities, any inability to develop programmed cellular immunotherapeutics, including NK cells and T cells derived from induced pluripotent cells, which are suitable for therapeutic applications, and the risk that programmed cellular immunotherapeutics or other product candidates that the Company may develop may not produce therapeutic benefits or may cause other unanticipated adverse effects. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Company’s periodic filings with the Securities and Exchange Commission, including but not limited to the Company’s Form 10-Q for the quarter ended June 30, 2015, and from time to time the Company’s other investor communications. The Company is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

CONTACT: Jesse Baumgartner
         Stern Investor Relations, Inc.
         212.362.1200
         jesse@sternir.com
Wednesday, October 28th, 2015 Uncategorized Comments Off on (FATE) Strengthens IP Position With New U.S. Patent

(FSNN) Leading East Coast Retailer of Wines and Spirits Migrates to Fusion Cloud

Customer Sought Secure, Single Source Cloud Solution

NEW YORK, NY–(October 28, 2015) – Fusion (NASDAQ: FSNN), a leading cloud services provider, announced today that a large and rapidly growing retailer of wines and spirits in the mid-Atlantic region has selected Fusion to connect all 15 of its locations to the Fusion cloud. Fusion’s fully integrated solution converges the retailer’s voice and data requirements, delivering award-winning cloud communications services that drive productivity while reducing costs, along with managed network services that guarantee quality of service while meeting the company’s rapidly expanding requirements for bandwidth. The retailer required a solution with integrated security to ensure the integrity of its information as it moves across the enterprise, and found that Fusion’s cloud-based Unified Threat Management (UTM) solution increases network efficiency while securing the company’s data.

Also key to the retailer’s decision to award Fusion a $360,000, three year contract for its cloud solution was its need to solve its immediate communications challenges while meeting its longer term goal of migrating to the cloud. Above all, the retailer was committed to a solution that satisfied its requirements for controlling the security and integrity of its data without increasing costs. The retailer’s IT team was impressed with Fusion’s cloud-based UTM solution which manages the firewall in the core rather than at each location, ensuring full access to the bandwidth.

The retailer was also impressed with Fusion’s feature-rich cloud voice solution, which will connect all 15 of its locations, including headquarters, overcoming its incumbent provider’s inherent service limitations, and providing unified access to information.

“Fusion takes pride in delivering cloud solutions that deliver peace of mind, solving the kinds of problems that keep CEOs and IT Directors up at night,” said Russell P. Markman, Fusion’s President of Business Services. “This leading retailer needed to synchronize solutions across the enterprise, driving efficiencies in the way it serves customers by using cloud communications to more effectively check inventory, answer customer questions and source product. The CEO’s primary concern was to be able to secure the transfer of information and directed his IT team to maintain a significant level of control. We’re delighted to deliver with a powerful administrative portal that gives the IT team complete access and confidence. We’re privileged to help this popular and growing retailer better serve its customers, now and in the future.”

About Fusion

Fusion is a leading provider of integrated cloud solutions to small, medium and large businesses. Fusion’s advanced, proprietary cloud service platform enables the integration of leading edge solutions in the cloud, including cloud communications, cloud connectivity, and cloud computing. Fusion’s innovative, yet proven cloud solutions lower our customers’ cost of ownership, and deliver new levels of security, flexibility, scalability, and speed of deployment. For more information, please visit www.fusionconnect.com.

Fusion Contact
Brian Coyne
212-201-2404
Email contact

Darrow Associates Contacts for Fusion
Jordan Darrow
(631) 367-1866
Email contact

Bernie Kilkelly
(516) 236-7007
Email contact

Wednesday, October 28th, 2015 Uncategorized Comments Off on (FSNN) Leading East Coast Retailer of Wines and Spirits Migrates to Fusion Cloud

(OPCO) MissionIR Exclusive Audio Interview With Executive Management

ATLANTA, GA–(Oct 28, 2015) – MissionIR today announces the online availability of its interview with OurPet’s Company (OTCQX: OPCO) co-founder and Chief Executive Officer Dr. Steven Tsengas, Chief Financial Officer Scott Mendes, as well as Dean Tsengas, co-founder, Vice President and general manager. The full audio interview is available at http://OPCO.MissionIR.com/interview.html.

OurPet’s develops, produces and markets various innovative pet accessory and consumable products. The company has 160 patents/patents pending, which facilitate its entrance into major national retailers. The OurPet’s interview starts off with a brief history of the company’s official launch 20 years ago.

“OurPet’s represented a dream that we had, to have a proprietary company that would be a virtual company … concentrate on product ideation, innovation, and the marketing and distribution of the products, which we felt would provide the highest level of return on investment, profitability, opportunity for growth … OurPet’s represented an opportunity to combine all the electronic and engineering experiences that we had, along with an understanding of the pathologies related to aging by pets and the problems they experience,” says Dr. Tsengas.

Dr. Tsengas discusses the overall pet industry, which at the time of the company’s founding was greatly lacking in innovation. OurPet’s decided to focus on three key segments of the industry — pet toys, feeding and storage, and waste and odor management — and its success in doing so is in the numbers. When OurPet’s launched its first trend-setting product in 1995, it was met with significant consumer response. In its first year of operations OurPet’s recorded $150,000 in annual sales. By the second year the figure jumped to $500,000 and now sits around $25 million.

“Our goal is to grow double to triple the industry growth, so our expectation this year is to grow at a high-digit number with an income of double-digit growth in terms of net income,” adds Dr. Tsengas.

In conjunction with this goal, CFO Mendes describes the company’s recently announced transition into a social media-driven awareness campaign to better communication with new investors and existing shareholders.

“We had taken a pretty traditional approach to IR … but we had not been seeing the trading activity that we felt the company deserved. So we decided to modernize our IR approach by getting into a more social media campaign … and get the OurPet’s story out,” he says.

The interview then touches on the company’s management team and the type of milestones it takes to become a high-growth corporation.

“One of the major jobs was, again, to develop and have the infrastructure to have seamless growth in the future, rather than a bumpy one … we feel we are at the point to support continuous improvement in revenue growth and profitability. One of the biggest things we had to accomplish was the branding of our company … that phase has been pretty well completed. In terms of product development, we have about 30 products in the mill at any one point in time. A lot of these products have been completed this past year increasingly will be launched in 2016 and beyond,” explains Dr. Tsengas.

On the operational side, OurPet’s has successfully established key partners around the world, which co-founder Dean Tsengas further details.

“It’s pretty diverse, as far as what the company’s offerings are and in order to focus on developing, design, marketing, distribution into the marketplace, what we’ve done is formed strategic partnerships with our key suppliers, both domestic and overseas … we’ve formed very close collaborative relationships with both our customers and our suppliers during the product development stage all the way through finished product and the full launch into the marketplace. This is what’s been the key toward our success, along with the key people in our company,” he says.

In conclusion, Dr. Tsengas flags upcoming company announcements with Japanese companies, and discusses the pet industry’s growth over the last 20 and how OurPet’s will continue to participate in the industry as a trend-setting leader.

About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. Through a full suite of investor relations and consultancy services, we help public companies develop and execute a strategic investor awareness plan as we’ve done for hundreds of others. Whether it’s capital raising, increasing awareness among the financial community, or enhancing corporate communications, we offer a variety of solutions to meet the objectives of our clients.

For more information, visit www.MissionIR.com

About The OurPet’s Company
The OurPet’s Company designs, produces and markets a broad line of innovative, trend-setting pet products and accessories sold under the OurPets and Pet Zone brands in the United States and overseas. OurPets and Pet Zone products are sold through leading pet specialty retailers, food, drug and mass merchandisers, direct-mail catalog and internet retailers. The OurPet’s Company has an extensive intellectual property portfolio with more than 160 patents in either issued or pending status. The company was named a Weatherhead Top 100 Fastest Growing Company in Northeast Ohio in 2013 and has been a Lake-Geauga County Fast Track 50 Hall of Fame local business success winner for the last eight consecutive years. In addition, The OurPet’s Company was named 2015 Business of the Year by the Painesville Area Chamber of Commerce. Investors and customers may visit www.ourpets.com and www.petzonebrand.com for more information about the Company, its products and brands.

Media
Peter Ostapowicz
Marketing Coordinator
440-354-6500 x141
postapowicz@ourpets.com

Investor Relations
Mission Investor Relations
Atlanta, Georgia
http://www.MissionIR.com
404-941-8975
Investors@MissionIR.com

Wednesday, October 28th, 2015 Uncategorized Comments Off on (OPCO) MissionIR Exclusive Audio Interview With Executive Management

(CHRS) to Present at Bloomberg Biosimilars Conference on November 2

REDWOOD CITY, Calif., Oct. 27, 2015  — Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it will participate in several panel discussions regarding development, regulatory, policy, analytics, commercialization, and other key industry issues at the Bloomberg Intelligence Biosimilars Conference. Juliana Reed, the President of the Biosimilar Forum and Coherus Vice President of Government Affairs, will be giving the keynote address.

The conference will be held on Monday, November 2 starting at 12:30 pm ET in New York City. Information regarding the discussions is available at http://b.bloomberg.com/2015Biosimilars-regform-sales.

About Coherus BioSciences, Inc.

Coherus is a pure-play biosimilar platform company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products.

For additional information, please visit www.coherus.com.

CONTACT:
Keith Vendola, M.D.
Investor Relations
Coherus BioSciences, Inc.
kvendola@coherus.com
+1 (650) 437-6239
Tuesday, October 27th, 2015 Uncategorized Comments Off on (CHRS) to Present at Bloomberg Biosimilars Conference on November 2

(INFN) Equinix Scales Global Network With Infinera Cloud Xpress

SUNNYVALE, CA–(October 27, 2015) – Infinera, provider of Intelligent Transport Networks, announced that Equinix selected the Infinera Cloud Xpress for datacenter interconnection in Tokyo, further broadening its global network with Infinera solutions. Tokyo is the second metro market after Hong Kong where Equinix is deploying the Infinera Cloud Xpress. The Infinera Cloud Xpress family offers hyper-scale density, operational simplicity and low power consumption to meet Equinix’s growing bandwidth demands.

Equinix is a global interconnection and datacenter company, operating International Business Exchange™ (IBX®) datacenters in 33 markets across 15 countries in the Americas, EMEA and Asia-Pacific regions. The Equinix IBX datacenters provide major networks and businesses a place to interconnect, building business ecosystems that have become vital for service providers, enterprise companies, and emerging businesses alike. IBX customers in 21 markets, including Tokyo and Hong Kong, can also use the Equinix Cloud Exchange service, which brings together cloud service providers and users, enabling them to establish affordable, private, high-performance connections to support hybrid cloud strategies.

Equinix selected the Infinera Cloud Xpress to serve the growing need for high bandwidth customer interconnections between its four IBX datacenters in Tokyo, which serve more than 260 companies. With the bandwidth provided by the Cloud Xpress, Equinix can continue to scale the number of customers it serves in all four IBX facilities and interconnect them as simply as if they were located in a single IBX facility.

Ideal for high performance datacenter interconnection, the Cloud Xpress leverages Infinera’s unique photonic integrated circuit technology to support up to one terabit per second (Tb/s) of input and output bandwidth in just two rack units with very low power. Designed for a datacenter operational model, with a rack-and-stack form factor, the Cloud Xpress delivers a full 500 gigabit per second (Gb/s) super-channel of wavelength division multiplexing (WDM) line-side bandwidth over 150 kilometers without any need for additional multiplexers or amplifiers, which is unique among datacenter interconnect products. The Cloud Xpress also enables efficient scaling with extremely simple provisioning and management, and open interfaces to plug into datacenter automation or SDN orchestration systems.

“Equinix is rapidly expanding across the globe,” said Teri Francis, vice president of technology at Equinix. “Cloud Xpress is an ideal solution for us to scale bandwidth in our Hong Kong and Tokyo networks and enhance our ability to connect our customers. Cloud Xpress is extremely simple to deploy and manage and fits our high-density, low power requirements. We are now looking forward to deploying the Cloud Xpress family in other markets globally to take advantage of these same scaling benefits.”

“The continued deployment of the Cloud Xpress by a leading datacenter operator like Equinix underscores the value Cloud Xpress brings to high-bandwidth datacenter interconnect,” said Stu Elby, senior vice president of cloud network strategy and technology at Infinera. “The Cloud Xpress, a purpose-built rack-and-stack datacenter platform, is ideal for operators in Asia where space limitation is a factor. The Cloud Xpress addresses the critical needs of datacenter operators and continues to gain traction in networks across the globe.”

Infinera introduced the Cloud Xpress family in 2014 delivering a cloud-optimized WDM solution to cloud service providers, Internet content providers, Internet Exchange service providers and other large-scale datacenter operators. Infinera recently expanded the Cloud Xpress family by shipping Cloud Xpress with 100 GbE, offering customers the choice of 10 GbE, 40 GbE and 100 GbE interfaces to meet their specific requirements.

About Infinera

Infinera (NASDAQ: INFN) provides Intelligent Transport Networks, enabling carriers, cloud operators, governments and enterprises to scale network bandwidth, accelerate service innovation and simplify optical network operations. Infinera’s end-to-end packet-optical portfolio is designed for long-haul, subsea, datacenter interconnect and metro applications. Infinera’s unique large scale photonic integrated circuits enable innovative optical networking solutions for the most demanding networks. To learn more about Infinera visit www.infinera.com, follow us on Twitter @Infinera and read our latest blog posts at blog.infinera.com.

Infinera and the Infinera logo are registered trademarks of Infinera Corporation. All other referenced trademarks are the property of their respective owners.

This press release contains forward-looking statements including, but not limited to, statements relating to the benefits of the features and functionality of Infinera’s Cloud Xpress family of products and future deployments of those products. These statements are not guarantees of results and should not be considered as an indication of future activity or future performance. Actual results may vary materially from these expectations as a result of various risks and uncertainties. Information about these risks and uncertainties, and other risks and uncertainties that affect Infinera’s business, is contained in the risk factors section and other sections of Infinera’s Quarterly Report on Form 10-Q for the quarter ended June 27, 2015 as filed with the SEC on July 31, 2015, as well subsequent reports filed with or furnished to the SEC. These reports are available on Infinera’s website at www.infinera.com and the SEC’s website at www.sec.gov. Infinera assumes no obligation to, and does not currently intend to, update any such forward-looking statements.

Media:
Anna Vue
Tel. +1 (916) 595-8157
avue@infinera.com

Investors:
Jeff Hustis
Tel: + 1 (408) 213-7150
jhustis@infinera.com

Tuesday, October 27th, 2015 Uncategorized Comments Off on (INFN) Equinix Scales Global Network With Infinera Cloud Xpress

(CERU) Announces Poster Presentations at the 2015 AACR-NCI-EORTC

Cerulean Pharma Inc. (NASDAQ:CERU), a clinical stage company developing nanoparticle-drug conjugates (NDCs), today announced that three Cerulean abstracts are included in the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held in Boston from November 5-9, 2015.

Title: CRLX101, an investigational nanoparticle-drug conjugate, localizes in human tumors and not in adjacent healthy tissue after intravenous dosing

Session ID: Poster Session B
Session Title: Drug Delivery
Poster Session: Saturday, November 7, 12:30 – 3:30 pm ET
Location: Exhibit Hall C-D
Abstract Number: B33
Presenter: Scott Eliasof, Ph.D., Cerulean

Title: Selective tumor localization of CRLX101, a novel nanoparticle-drug conjugate

Session ID: Poster Session B
Session Title: Drug Delivery
Poster Session: Saturday, November 7, 12:30 – 3:30 pm ET
Location: Exhibit Hall C-D
Abstract Number: B37
Presenter: Christian G. Peters, Ph.D., Cerulean

Title: In vitro and in vivo studies demonstrating sustained drug release for multiple anticancer payloads and improved anticancer effects of a cabazitaxel β-cyclodextrin-PEG copolymer-based nanoparticle-drug conjugate (NDC)

Session ID: Poster Session B
Session Title: Therapeutic Agents: Other
Poster Session: Saturday, November 7, 12:30 – 3:30 pm ET
Location: Exhibit Hall C-D
Abstract Number: B176
Presenter: Chester Metcalf III, Ph.D., Cerulean

All of these abstracts can be viewed on the AACR website www.aacr.org.

About CRLX101

CRLX101 is a nanoparticle-drug conjugate (NDC) designed to concentrate in tumors and slowly release its anti-cancer payload, camptothecin, inside tumor cells. CRLX101 inhibits topoisomerase 1 (topo 1), which is involved in cellular replication, and also inhibits hypoxia-inducible factor-1α (HIF-1α), which research suggests is a master regulator of cancer cell survival mechanisms. CRLX101 has shown activity in four different tumor types, both as monotherapy and in combination with other cancer treatments. CRLX101 is in Phase 2 clinical development and has been dosed in more than 300 patients. The U.S. FDA has granted CRLX101 Orphan Drug designation for the treatment of ovarian cancer and Fast Track designation in combination with Avastin® in metastatic renal cell carcinoma.

About CRLX301

CRLX301 is a dynamically tumor-targeted NDC designed to concentrate in tumors and slowly release its anti-cancer payload, docetaxel, inside tumor cells. In preclinical studies, CRLX301 delivers up to 10 times more docetaxel into tumors, compared to an equivalent milligram dose of commercially available docetaxel and was similar to or better than docetaxel in seven of seven animal models, with a statistically significant survival benefit seen in five of those seven models. In addition, preclinical data show that CRLX301 had lower toxicity than has been reported with docetaxel in similar preclinical studies. CRLX301 is currently in Phase 1/2a clinical development.

About Cerulean Pharma

The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting Platform to create a portfolio of NDCs designed to selectively attack tumor cells, reduce toxicity by sparing the body’s normal cells, and enable therapeutic combinations. Our first platform-generated candidate, CRLX101, is in multiple clinical trials in combination with other cancer treatments, all of which aim to unlock the power of combination therapy. Our second platform-generated candidate, CRLX301, is in a Phase 1/2a clinical trial. For more information, please visit www.ceruleanrx.com.

About Cerulean’s Dynamic Tumor Targeting Platform

Cerulean’s Dynamic Tumor Targeting Platform creates NDCs that are designed to provide safer and more effective cancer treatments. We believe our NDCs concentrate their anti-cancer payloads inside tumors while sparing normal tissue because they are small enough to pass through the “leaky” vasculature present in tumors but are too large to pass through the wall of healthy blood vessels. Once inside tumors, our NDCs enter tumor cells where they slowly release anti-cancer payloads from within the tumor cells.

Cautionary Note on Forward Looking Statements

Any statements in this press release about our future expectations, plans and prospects, including statements about the clinical development of our product candidates, statements about our estimated research and development expenses and sufficiency of cash to fund specified use of cash and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “hypothesize,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals, availability of funding sufficient for our foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the “Risk Factors” section of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2015, and in other filings that we make with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update any forward-looking statements included in this press release.

Avastin is a registered trademark of Genentech, Inc.

 

Cerulean Pharma Inc.
Nicole P. Jones, 617-551-9606
Director, Investor Relations and
Corporate Communications
njones@ceruleanrx.com

Tuesday, October 27th, 2015 Uncategorized Comments Off on (CERU) Announces Poster Presentations at the 2015 AACR-NCI-EORTC

(RITT) Tianjin City Rail Network Utilizes RiT’s PatchView

Intelligent Infrastructure Management Provides Real-Time Status and Management of 6,000 Intelligent Ports Used by 22 Transit Lines

TEL AVIV, Israel, Oct. 27, 2015  — RiT Technologies (NASDAQ:RITT), a leading provider of Converged Infrastructure Management Solutions that enable companies to maximize utilization and security of their network infrastructure, announced today that the Tianjin City Rail Transit of China has deployed RiT’s PatchView™ Intelligent Infrastructure Management (IIM) solution to gain real-time visibility and control of their network while increasing availability and operational efficiency. The PatchView IIM solution manages 6,000 intelligent ports used by 22 transit lines. RiT also provides the fiber optic cable line subsystem of this backbone communication system. The system was provided in partnership with the China Railway Signal & Communication Shanghai Engineering Bureau Group.

“PatchView will serve as the backbone to Tianjin City Rail Network’s control center communications, giving them an up-to-the-minute view of the status of all devices,” said Feng Zhang with the China Railway Signal & Communication Shanghai Engineering Bureau Group. “This solution provides real-time management and monitoring, via graphical simulation, of all subway stations and routes, and creates alarms for potential network failures that can be responded to quickly to ensure uninterrupted service.”

PatchView gives users a comprehensive real-time view of the network, including all IT assets, pinpointing their exact location and status at the rack, cabinet, room, building and site levels. This always-on, constant monitoring of the network has the ability to flag network problems and identify points of failure before they result in downtime. PatchView also automates regular network maintenance helping streamline work, eliminate human error and reduce maintenance costs.

“With the growing role of ITSM with RiT’s connectivity solutions to ensure uninterrupted service, having the ability to manage all connected components in real-time is now the rule and not the exception,” said Yossi Ben-Harosh, President and CEO of RiT Technologies. “We are honored to be at the forefront of IIM and to offer PatchView to Tianjin City Rail to provide them with the required visibility into their railway infrastructure to deliver top notch services while enabling them to maximize their resources and optimize capacity.”

About RiT Technologies

RiT Technologies (NASDAQ:RITT) is a leading provider of converged IT infrastructure management and connectivity solutions that improve network utilization, streamline infrastructure operations and enhance data security, reduce network operation cost and optimize future investments.

RiT offers a platform that provides a unified way to manage converged systems and services to improve network utilization, streamline infrastructure operations, reduce cost and enhance data security. RiT’s platform includes connectivity solutions such as IIM, (Intelligent Infrastructure Management), converged infrastructure management software, and indoor optical wireless technology.

Deployed around the world in data centers, large corporations, government agencies, financial institutions, telecommunications, airport authorities, healthcare organizations and educational facilities. RiT’s shares are traded on the NASDAQ Capital Market under the symbol RITT.

Safe Harbor Statement

In this press release, all statements that are not purely about historical facts, including, but not limited to, those in which we use the words “believe,” “anticipate,” “expect,” “plan,” “intend,” “estimate”, “forecast”, “target”, “could” and similar expressions, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. While these forward-looking statements represent our current judgment of what may happen in the future, actual results may differ materially from the results expressed or implied by these statements due to numerous important factors, including, but not limited to, those described under the heading “Risk Factors” in our most recent Annual Report filed with the Securities and Exchange Commission (SEC) on Form 20-F, which may be revised or supplemented in subsequent reports filed with the SEC. These factors include, but are not limited to, the following: our ability to raise additional financing, if required; the continued development of market trends in directions that benefit our sales; our ability to maintain and grow our revenues; our dependence upon independent distributors, representatives and strategic partners; our ability to develop new products and enhance our existing products; the availability of third-party components used in our products; the economic condition of our customers; the impact of government regulation; and the economic and political situation in Israel. Except as otherwise required by applicable law, we expressly disclaim any obligation to update the forward-looking statements in this press release, whether as a result of new information, future events or otherwise.

CONTACT: Kobi Haggay
         VP Products and Marketing
         M: +972.54.4338382
         kobi.haggay@rittech.com
         www.rittech.com

         Monica Maron
         Spicetree Communications
         Mobile: +972-54-5429529
         monica.maron@spicetreecom.com
Tuesday, October 27th, 2015 Uncategorized Comments Off on (RITT) Tianjin City Rail Network Utilizes RiT’s PatchView

(ISIS) to Host Webcast to Review ISIS-TTR Rx Data

– Webcast scheduled on Tuesday, November 3 at 8:00 a.m. Eastern Time

CARLSBAD, Calif., Oct. 27, 2015  — Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host a live webcast on Tuesday, November 3 at 8:00 a.m. Eastern Time to review ISIS-TTRRx data presented at the 1st European Congress of Hereditary ATTR Amyloidosis and provide Phase 3 development plan update.

Interested parties may listen to the call by dialing 877-443-5662 or access the webcast at www.isispharm.com.  A webcast replay will be available for a limited time at the same address.

ABOUT ISIS PHARMACEUTICALS, INC.
Isis is the leading company in RNA-targeted drug discovery and development focused on developing drugs for patients who have the highest unmet medical needs, such as those patients with severe and rare diseases.  Using its proprietary antisense technology, Isis has created a large pipeline of first-in-class or best-in-class drugs, with over a dozen drugs in mid- to late-stage development.  Drugs currently in Phase 3 development include volanesorsen, a drug Isis is developing and plans to commercialize through its wholly owned subsidiary, Akcea Therapeutics, to treat patients with familial chylomicronemia syndrome and familial partial lipodystrophy; ISIS-TTRRx, a drug Isis is developing with GSK to treat patients with all forms of TTR amyloidosis; and ISIS-SMNRx, a drug Isis is developing with Biogen to treat infants and children with spinal muscular atrophy.  Isis’ patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS’ FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding Isis Pharmaceuticals’ financial position and outlook, Isis’ business, and the therapeutic and commercial potential of Isis’ technologies and products in development.  Any statement describing Isis’ goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis’ forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis’ programs are described in additional detail in Isis’ annual report on Form 10-K for the year ended December 31, 2014, and its most recent quarterly report on Form 10-Q, which are on file with the SEC.  Copies of these and other documents are available from the Company.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  Akcea Therapeutics™ is a trademark of Isis Pharmaceuticals, Inc.  KYNAMRO® is a registered trademark of Genzyme Corporation.

Tuesday, October 27th, 2015 Uncategorized Comments Off on (ISIS) to Host Webcast to Review ISIS-TTR Rx Data

(OGES) Featured on The Princeton Research Money Info Show

Oakridge Global Energy Solutions was recently featured on The Princeton Research Money Info show, which is broadcast live on the internet and on the air in Port St. Lucie, Florida. During the show, investing experts Mike King and Charles Moskowitz interviewed Steve Barber, executive chairman and chief executive officer of Oakridge, about the company’s recent success. As the company behind the only ‘Made in the USA’ lithium-ion battery, Oakridge is in a strong strategic position to capitalize on the global market opportunity presented by the energy storage industry, which is expected to eclipse $70 billion in sales by 2020.

In the interview, Barber outlined the recent restructuring of Oakridge. The company’s reorganization was funded through a $39 million investment by the Precept Fund – an international, five family investment group from Australia, Japan and Switzerland with a long-term view of building and owning profitable businesses. Through this significant investment, Barber and the Oakridge management team have reinvented the company, better positioning it to compete in a market with sustainable demand and favorable markups. However, Oakridge’s mission goes beyond fast growth, as Barber indicated on the show. Instead, the company is being built as a long-term addition to the global energy storage market, which is rapidly evolving in search of dependable, high-quality offerings.

This market evolution is demonstrated by the number of lithium battery manufacturers currently in operation. At one time, Asian markets experienced a boom, and roughly 1,400 lithium battery manufacturers occupied the space. Over time, inferior quality products and unsustainable pricing models have eliminated a substantial portion of these battery producers. Analysts expect the global number of lithium battery manufacturers to fall to about 250 by next year.

Oakridge is combatting current market conditions by creating superior quality batteries that address the specific needs of consumers. While industry giants such as Tesla (NASDAQ: TSLA) and Panasonic (OTC: PSRFY) remain limited to producing standardized batteries in enormous quantities, Barber noted Oakridge’s ability to create specialized products that maximize the company’s market impact and enable strong returns for shareholders.

To listen to the full interview, visit www.princetonresearch.com/radio-shows

Tuesday, October 27th, 2015 Uncategorized Comments Off on (OGES) Featured on The Princeton Research Money Info Show